147 related articles for article (PubMed ID: 35670639)
21. Giant umbilical cord and hypoglycemia in an infant with Proteus syndrome.
Saito T; Nakane T; Narusawa M; Yagasaki H; Nemoto A; Naito A; Sugita K
Am J Med Genet A; 2018 May; 176(5):1222-1224. PubMed ID: 29681107
[TBL] [Abstract][Full Text] [Related]
22. Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
Akgumus G; Chang F; Li MM
J Mol Diagn; 2017 Jul; 19(4):487-497. PubMed ID: 28502730
[TBL] [Abstract][Full Text] [Related]
23. Dermatologic findings in individuals with genetically confirmed Proteus syndrome.
Pithadia DJ; Cartron AM; Biesecker LG; Darling TN
Pediatr Dermatol; 2021 Jul; 38(4):794-799. PubMed ID: 34105192
[TBL] [Abstract][Full Text] [Related]
24. Characterization of thrombosis in patients with Proteus syndrome.
Keppler-Noreuil KM; Lozier JN; Sapp JC; Biesecker LG
Am J Med Genet A; 2017 Sep; 173(9):2359-2365. PubMed ID: 28627093
[TBL] [Abstract][Full Text] [Related]
25. First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.
Leoni C; Gullo G; Resta N; Fagotti A; Onesimo R; Schwartz B; Kazakin J; Abbadessa G; Crown J; Collins CD; Ranieri C; Scambia G; Zampino G
Am J Med Genet A; 2019 Jul; 179(7):1319-1324. PubMed ID: 31058421
[TBL] [Abstract][Full Text] [Related]
26. Mutant AKT1 in Proteus syndrome.
Marsh DJ; Trahair TN; Kirk EP
N Engl J Med; 2011 Dec; 365(22):2141-2; author reply 2142. PubMed ID: 22129268
[No Abstract] [Full Text] [Related]
27. Fibroadipose hyperplasia versus Proteus syndrome: segmental overgrowth with a mosaic mutation in the PIK3CA gene.
Youssefian L; Vahidnezhad H; Baghdadi T; Ghaznavi A; Li Q; Tabrizi M; Uitto J
J Invest Dermatol; 2015 May; 135(5):1450-1453. PubMed ID: 25602158
[No Abstract] [Full Text] [Related]
28. Clinical Phenotype and Bone Biopsy Characteristics in a Child with Proteus Syndrome.
Al Kaissi A; Misof BM; Laccone F; Blouin S; Roschger P; Kircher SG; Shboul M; Mindler GT; Girsch W; Ganger R
Calcif Tissue Int; 2021 Nov; 109(5):586-595. PubMed ID: 34003338
[TBL] [Abstract][Full Text] [Related]
29. Molecular diagnosis of somatic overgrowth conditions: A single-center experience.
Lalonde E; Ebrahimzadeh J; Rafferty K; Richards-Yutz J; Grant R; Toorens E; Marie Rosado J; Schindewolf E; Ganguly T; Kalish JM; Deardorff MA; Ganguly A
Mol Genet Genomic Med; 2019 Mar; 7(3):e536. PubMed ID: 30761771
[TBL] [Abstract][Full Text] [Related]
30. Proteus Syndrome: Case Report with Anatomopathological Correlation.
Arredondo Montero J; Bronte Anaut M; López-Gutiérrez JC
Fetal Pediatr Pathol; 2022 Oct; 41(5):861-864. PubMed ID: 34668833
[No Abstract] [Full Text] [Related]
31. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.
Keppler-Noreuil KM; Baker EH; Sapp JC; Lindhurst MJ; Biesecker LG
Am J Med Genet A; 2016 Oct; 170(10):2605-10. PubMed ID: 27550858
[TBL] [Abstract][Full Text] [Related]
32. Extending the spectrum of AKT1 mosaicism: not just the Proteus syndrome.
Polubothu S; Al-Olabi L; Wilson L; Chong WK; Kinsler VA
Br J Dermatol; 2016 Sep; 175(3):612-4. PubMed ID: 26872686
[No Abstract] [Full Text] [Related]
33. Phenotypic and genetic spectrum of isolated macrodactyly: somatic mosaicism of PIK3CA and AKT1 oncogenic variants.
Tian W; Huang Y; Sun L; Guo Y; Zhao S; Lin M; Dong X; Zhong W; Yin Y; Chen Z; Zhang N; Zhang Y; Wang L; Lin J; Yan Z; Yang X; Zhao J; Qiu G; Zhang J; Wu Z; Wu N;
Orphanet J Rare Dis; 2020 Oct; 15(1):288. PubMed ID: 33054853
[TBL] [Abstract][Full Text] [Related]
34. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).
Biesecker LG; Edwards M; O'Donnell S; Doherty P; MacDougall T; Tith K; Kazakin J; Schwartz B
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 32014856
[TBL] [Abstract][Full Text] [Related]
35. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.
Lindhurst MJ; Yourick MR; Yu Y; Savage RE; Ferrari D; Biesecker LG
Sci Rep; 2015 Dec; 5():17162. PubMed ID: 26657992
[TBL] [Abstract][Full Text] [Related]
36. Heterozygous somatic activating AKT1 mutation in a case of Proteus syndrome with mental retardation.
Yang Z; Xu Z; Sun YJ; Ma L
J Dermatol; 2014 Feb; 41(2):188-9. PubMed ID: 24387135
[No Abstract] [Full Text] [Related]
37. Proteus syndrome: A case report and review of the literature.
Ou M; Sun Z; Zhu P; Sun G; Dai Y
Mol Clin Oncol; 2017 Mar; 6(3):381-383. PubMed ID: 28451417
[TBL] [Abstract][Full Text] [Related]
38. Clinical differentiation between Proteus syndrome and hemihyperplasia: description of a distinct form of hemihyperplasia.
Biesecker LG; Peters KF; Darling TN; Choyke P; Hill S; Schimke N; Cunningham M; Meltzer P; Cohen MM
Am J Med Genet; 1998 Oct; 79(4):311-8. PubMed ID: 9781913
[TBL] [Abstract][Full Text] [Related]
39. AKT1 gene mutation levels are correlated with the type of dermatologic lesions in patients with Proteus syndrome.
Lindhurst MJ; Wang JA; Bloomhardt HM; Witkowski AM; Singh LN; Bick DP; Gambello MJ; Powell CM; Lee CR; Darling TN; Biesecker LG
J Invest Dermatol; 2014 Feb; 134(2):543-546. PubMed ID: 23884311
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
